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standard treatment for this age group. Several recent studies suggest 
superiority of combination CT, but little is known about QoL during 
CT. Also better assessments are needed to select elderly pts suitable for 
combination CT. The aim of this study was to investigate the effect of 
both platinum-based regimens on changes in QoL and the tolerability 
of these treatments in elderly NSCLC pts.
Methods: Eligible were pts ≥ 70 years with advanced NSCLC. They 
received carboplatin (AUC 5 day 1)-gemcitabine (1250 mg/m2 days 1 
and 8) or carboplatin (AUC 5 day 1)-paclitaxel (175 mg/m2 day 1), q 
3 weeks, for a maximum of 4 cycles. Darbepoetin was started if Hb < 
11 g/dL. Primary endpoint was the change in global QoL from baseline 
compared with week 18, using the EORTC QLQ-C30. Among the sec-
ondary endpoints were toxicity, response rate and survival. In addition, 
the value of a comprehensive geriatric assessment (CGA) was used.
Results: 182 pts were randomized. At the time of this analysis informa-
tion was available on 168 pts. Mean age was 75 yrs (range 70-85). PS 
= 0 in 30%, 1 in 57% and 2 in 13%. 64% of pts completed all 4 cycles, 
10% stopped treatment prematurely due to toxicity, 13% due to PD. 
Toxicity related dose-reductions occurred in 28 and 8% of pts and 
dose-delays in 15 and 3% of pts in the CG and CP arm, respectively. 
Overall, grade III/IV toxicity occurred in 65% of pts (75% in CG arm, 
56% in CP arm), toxicity related SAEs in 17% (20% in CG arm, 15% 
in CP arm), and 36% experienced ≥ grade 2 neurological toxicity (30% 
CG arm, 43% CP arm). Response rates were 28% in the CG arm vs 
20% in the CP arm. Median survival and progression-free survival were 
7.7 and 4.7 months for the CG arm and 6.6 and 4.4 months for the CP 
arm, respectively. 56 % of pts in the CG arm and 49% in the CP arm 
completed both the QoL questionnaires at baseline and after 18 weeks. 
Mean global QoL score at baseline did not differ between both arms 
(66% for GC and CP). After 18 weeks the mean QoL score for the CG 
arm had decreased by 2% and for the CP arm by 8% (NS). Further-
more, changes in Qol scores over the period of 18 weeks did not differ 
signiﬁcantly between both treatment arms. For experiencing grade 
III/IV toxicity related SAEs, neurological toxicities and for ﬁnishing all 
cycles, the use of a CGA was of predictive value.
Conclusions: In elderly patients with advanced NSCLC differences in 
treatment-related toxicity from gemcitabine and paclitaxel administered 
with carboplatin have no differential inﬂuence on QoL. Response and 
survival rates are similar for both groups. 
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Background: The combination of docetaxel and cisplatin is an ef-
fective ﬁrst-line chemotherapy for advanced NSCLC. However, the 
recommended three-weekly schedule is frequently associated with 
neutropenia and neutropenic infections. Moreover, the relatively long 
hydration required with cisplatin given every three weeks makes outpa-
tient treatment more difﬁcult. We assessed the efﬁcacy and tolerability 
of weekly docetaxel-cisplatin, which may be better tolerated than the 
standard regimen.
Methods: Patients (pts) with histologically conﬁrmed stage UICC IIIB 
(malignant effusion) or IV NSCLC received docetaxel (35 mg/m2, 30 
min. infusion) and cisplatin (25 mg/m2, 30-min. infusion) on days 1, 8, 
and 15, every 4 weeks for 4-6 cycles. Pts received ondansetron 8 mg iv 
and dexamethasone 8 mg iv preceding every day of chemotherapy and 
oral dexamethasone 2 x 4 mg daily from the day before until the day 
after chemotherapy. NK1-antagonists were given at the investigator’s 
discretion. Most pts were treated in an outpatient department. Safety 
was assessed using CTCAE v3.0. The primary endpoint was response 
rate (RECIST).
Results: 45 pts were included; efﬁcacy and tolerability data were avail-
able for 43 pts. 12/45 pts achieved an objective response (11 partial; 
1 complete; ITT response rate 27%). Median time to progression was 
3.9 months. Pts received a median of 3 full cycles. 4 pts (9%) required 
dose reductions. No cases of neutropenic fever/infections or grade 2-4 
thrombocytopenia were observed. One pt (2%) experienced grade 3/4 
nausea/vomiting. 5 pts died during therapy for reasons not unequivo-
cally attributable to tumor progression (bacterial meningitis with nor-
mal neutrophil counts [n=1], pneumonia with normal neutrophil counts 
[n=1], pulmonary arterial embolism [n=1], unknown [n=2]).
Conclusions: Weekly docetaxel-cisplatin was well tolerated. The 
schedule can be safely administered with relatively low hydration vol-
umes in an outpatient setting. Survival data will be presented.
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Metastatic NSCLC clinical trials evaluating the role of palliative che-
motherapy often underrepresent or exclude patients with brain metas-
tases. The prognosis for this subgroup of patients remains poor and the 
advantage of chemotherapy, after deﬁnitive whole brain radiotherapy 
(WBRT), remains unclear. A retrospective chart review of NSCLC pa-
tients presenting with synchronous brain metastases in Alberta, Canada 
from 2000-2004 was undertaken to examine the possible beneﬁts of 
chemotherapy following WBRT. 497 chemonaive NSCLC patients with 
brain metastases received brain radiotherapy from 2000-2004, but only 
30 patients (6%) received subsequent chemotherapy. Of the 30 patients, 
the median age was 54 years (range 29 to 69 years), 40% were male, 
87% had an ECOG performance status ≤ 2 and 60% had adenocarci-
noma subtype of NSCLC. The treatment of the brain metastases, prior 
to chemotherapy, consisted primarily of WBRT (62% of patients irradi-
ated with 30 Gy in 10 fractions; 38% patients irradiated with 20 Gy in 
5 fractions), whereas only one patient underwent stereotactic radiosur-
gery. An intracranial response or stable disease was observed in 66% 
of patients. When treated with chemotherapy after brain radiotherapy, 
97% received a platinum-based doublet for a median of 4 cycles (range 
1-6). The response rate to ﬁrst-line chemotherapy was 30%, and 10 
